González-Duarte, Alejandra
Berk, John L.
Quan, Dianna
Mauermann, Michelle L.
Schmidt, Hartmut H.
Polydefkis, Michael
Waddington-Cruz, Márcia
Ueda, Mitsuharu
Conceição, Isabel M.
Kristen, Arnt V.
Coelho, Teresa
Cauquil, Cécile A.
Tard, Céline
Merkel, Madeline
Aldinc, Emre
Chen, Jihong
Sweetser, Marianne T.
Wang, Jing Jing
Adams, David
Funding for this research was provided by:
Alnylam Pharmaceuticals (N/A)
Article History
Received: 19 August 2019
Revised: 21 October 2019
Accepted: 23 October 2019
First Online: 14 November 2019
Change Date: 7 February 2020
Change Type: Correction
Change Details: The original version of this article unfortunately contained a mistake.
Compliance with ethical standards
:
: AGD reports serving as a consultant for Alnylam Pharmaceuticals and Pfizer. JB reports compensation for study investigator and coordinator time and hospital services from Alnylam Pharmaceuticals during the study. Outside of the submitted work, JB acknowledges personal fees from Alnylam Pharmaceuticals for visiting professor presentations, from Akcea Therapeutics for attendance at an advisory committee, from Intellia Therapeutics and Corino Therapeutics for scientific advisory boards and also reports study investigator and coordinator compensation from Pfizer Inc. DQ reports grants received from Alnylam Pharmaceuticals. MLM reports research grants from Alnylam Pharmaceuticals and Ionis Pharmaceuticals. HS has nothing to disclose. MP reports receiving personal fees and serving as a principal investigator and consultant for Alnylam Pharmaceuticals during the work. Outside of the study work MP reports personal fees, and serving as a principal investigator and consultant for Alnylam Pharmaceuticals, Ionis Pharmaceuticals, and Pfizer Inc. MWC received honoraria from NHI, Prothena, FoldRx, Akcea Therapeutics, Pfizer Inc., Alnylam Pharmaceuticals, PTC and Genzyme for travel expenses related to presentations at medical meetings, for acting as a consultant and as a principal investigator in clinical trials. MU reports personal fees and non-financial support for travel, participating in advisory boards, and speaker fees from Alnylam Pharmaceuticals and Pfizer Inc. outside of the submitted work. IC reports receiving personal fees and serving as a principal investigator for Alnylam Pharmaceuticals. AVK received honoraria and fees for lectures and speakers bureaus from Alnylam Pharmaceuticals, Akcea Therapeutics, and Pfizer Inc. TC reports personal fees from Alnylam Pharmaceuticals and personal fees and financial support to attend scientific meetings from Pfizer Inc., outside of the submitted work. CC acknowledges speaker honoraria from Alnylam Pharmaceuticals, Pfizer Inc., and Akcea Therapeutics, outside of the submitted work. CT has nothing to disclose. MM, EA, JC, MS, JJW are all employees of Alnylam Pharmaceuticals and MS reports owning Alnylam Pharmaceutical stock options. DA reports consultancy fees and clinical grants from Alnylam Pharmaceuticals, and clinical grants and symposium speaker fees from Pfizer Inc., outside of the submitted work.
: The protocol was approved by central and local institutional review boards or ethics committees and conducted in accordance with the International Conference on Harmonization for Good Clinical Practice, the Declaration of Helsinki, and the 1996 Health Insurance Portability and Accountability Act.